TARGET-VM: A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations

Sponsor

Murdoch Childrens Research Institute (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05983159

Collaborator

Peter MacCallum Cancer Centre, Australia (Other), Royal Children's Hospital (Other)

Enrollment

Location

Arms

Anticipated Duration (Months)

0.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Recent studies have demonstrated that growth of vascular malformations can be driven by genetic variants in one of 2 signalling pathways. Targeted drugs specific to these pathways have been developed and shown to be effective in treating cancer. This study will describe the effectiveness of (i) 12 months of alpelisib therapy for participants with slow-flow vascular malformations and a gene mutation in one of these signalling pathways (module 1) and (ii) 12 months of mirdametinib therapy for participants with fast-flow vascular malformations and a gene mutations in the other signalling pathway (module 2).

Condition or Disease	Intervention/Treatment	Phase
Slow-Flow Vascular Malformation Fast-Flow Vascular Malformation Vascular Malformations Venous Malformation Lymphatic Malformation, Low Flow Lymphatic Malformation Lymphangioma Arteriovenous Malformations Venous Malformation, Low Flow Cystic Hygroma Vascular Anomaly Vascular Anomalies PI3K Gene Mutation MAP2K1 Gene Mutation PIK3CA-related Overgrowth Spectrum Arteriovenous Malformation (AVM) KRAS G12C KRAS G12D	Drug: Alpelisib Drug: Mirdametinib	Phase 2

Detailed Description

TARGET-VM is a modular open-label, signal seeking, phase II trial of targeted therapies for patients with vascular malformations. Patients with vascular malformations which are refractory to standard therapies, or in whom standard therapy is not appropriate, are potentially eligible for the clinical trial. Vascular malformations will be classified as slow-flow or fast-flow lesions using established clinical criteria. Genetic testing to identify causative variants in genes affecting the phosphoinositide 3-kinase (PI3K) signalling pathway for slow-flow vascular malformations or the Mitogen-Activated Protein Kinase (MAPK) signalling pathway for fast-flow vascular malformations must be performed using research protocols or commercial testing assays that are external to this clinical trial.

The study consists of individual modules, each evaluating the clinical efficacy of 12 months of targeted therapy. The treatment modules are:

Module 1 - Treatment for slow-flow vascular malformations Eligible patients with slow-flow vascular malformations with an identified causative variant in the PI3K signalling pathway will receive alpelisib, an oral alpha-specific PI3-kinase inhibitor for a total duration of 12 months as monotherapy (treatment period), followed by 6 months of follow-up (follow-up period).
Module 2 - Treatment for fast-flow vascular malformations Eligible patients with fast-flow vascular malformations with an identified causative variant in the MAPK signalling pathway will receive mirdametinib, an investigational oral MEK inhibitor for a total duration of 12 months as monotherapy (treatment period), followed by 6 months of follow-up (follow-up period).

TARGET-VM will be conducted only in Victoria, Australia.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

30 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

i) Participants with slow-flow vascular malformations with an eligible gene mutation will receive 12 months of treatment with open-label alpelisib. )ii Participants with fast-flow vascular malformations with an eligible gene mutation will receive 12 months of treatment with open-label mirdametinibParticipants with slow-flow vascular malformations with an eligible gene mutation will receive 12 months of treatment with open-label alpelisib. )ii Participants with fast-flow vascular malformations with an eligible gene mutation will receive 12 months of treatment with open-label mirdametinib

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Modular Open Label, Signal Seeking, Phase II Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations (TARGET-VM)

Anticipated Study Start Date :

Sep 1, 2023

Anticipated Primary Completion Date :

Sep 1, 2026

Anticipated Study Completion Date :

Sep 1, 2028

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Module 1: Slow-flow vascular malformations Slow-flow vascular malformations with identified causative variants in the phosphoinositide 3-kinase (PI3K) signalling pathway will receive alpelisib (provided by Novartis Pharmaceuticals), an oral alpha-specific PI3-kinase inhibitor for a total duration of 12 months as monotherapy, followed by 6 months of follow-up.	Drug: Alpelisib Oral alpha-specific PI3-kinase inhibitor Other Names: BYL719
Experimental: Module 2: Fast-flow vascular malformations Fast-flow vascular malformations with identified causative variants in the RAS-MEK-ERK signalling pathway will receive mirdametinib (provided by SpringWorks Therapeutics, Inc.), an investigational oral MEK inhibitor for a total duration of 12 months as monotherapy, followed by 6 months of follow-up.	Drug: Mirdametinib An investigational oral MEK inhibitor

Arm

Intervention/Treatment

Experimental: Module 1: Slow-flow vascular malformations

Slow-flow vascular malformations with identified causative variants in the phosphoinositide 3-kinase (PI3K) signalling pathway will receive alpelisib (provided by Novartis Pharmaceuticals), an oral alpha-specific PI3-kinase inhibitor for a total duration of 12 months as monotherapy, followed by 6 months of follow-up.

Drug: Alpelisib

Oral alpha-specific PI3-kinase inhibitor

Other Names:

BYL719

Experimental: Module 2: Fast-flow vascular malformations

Fast-flow vascular malformations with identified causative variants in the RAS-MEK-ERK signalling pathway will receive mirdametinib (provided by SpringWorks Therapeutics, Inc.), an investigational oral MEK inhibitor for a total duration of 12 months as monotherapy, followed by 6 months of follow-up.

Drug: Mirdametinib

An investigational oral MEK inhibitor

Outcome Measures

Primary Outcome Measures

The number of participants who achieve or exceed a predetermined threshold of improvement in their most significant symptom at 12 months based on the Vascular Malformation Patient Specific Outcome Measure (VM-PSOM). [At 12 months]
Vascular malformations present with a range of different symptoms. Therefore, there is no single outcome measure that can capture the effectiveness of a systemic treatment across different patients. Thus for this study, an individualised primary outcome for each patient informed by their symptoms will be used, termed the Vascular Malformation Patient Specific Outcome Measure (VM-PSOM). The study "Outcome Committee" will define an individualised primary outcome for each patient informed by their symptoms and vascular malformation features prior to starting trial treatments. The VM-PSOM endpoint will therefore define a binary outcome for each patients (achieved or failed to reach the threshold improvement in the chosen measure).

Secondary Outcome Measures

The number of participants who achieve or exceed a predetermined threshold of improvement in their most significant symptom at the 168-day timepoint based on the Vascular Malformation Patient Specific Outcome Measure (VM-PSOM). [12 months, 168-day follow-up]
VM-PSOM response at the 168 day follow-up visit assessment compared with the 12 month (end-of-treatment) VM-PSOM.
The number of participants with an objective response (defined as ≥ 20% reduction from index date in the sum of measurable target lesion volume) by volumetric analysis on MRI. [Baseline, 12 months]
Objective response rate by volumetric MRI assessment comparing 12 month (end-of-treatment) MRI with baseline MRI. MRI scan will only be performed in patients where their vascular malformation is feasibly evaluable by MRI scan. Objective response is defined as ≥ 20% reduction from index date in the sum of measurable target lesion volume by volumetric analysis on MRI.
Change in symptoms score as recorded on the OVAMA (Outcome measures for VAscular MAlformations) questionnaire. [Time frame: Baseline, 12 months]
The mean scores in the OVAMA (Outcome measures for VAscular MAlformations) questionnaire will be calculated and analysed at specified time points. This is a set of questions developed specifically to measure symptom burden from vascular malformations. These questions are open-ended to allow the subject to describe how they feel. The questions are more tightly structured to allow comparison of answers to other people with vascular malformations. The questions have been designed in a way to determine if symptoms are getting better over time.
Change in symptoms score as recorded on the OVAMA (Outcome measures for VAscular MAlformations) which is a set of questions developed specifically to measure symptom burden from vascular malformations. [Time frame: 12 months, Day 168 follow-up]
The mean scores in the OVAMA (Outcome measures for VAscular MAlformations) questionnaire will be calculated and analysed at specified time points.
The number of patients who experience adverse events as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5. [From Baseline to Day 168 follow-up]

Eligibility Criteria

Criteria

Ages Eligible for Study:

2 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Adult or paediatric patient, 2 years of age or over where Body Surface Area (BSA) is greater than or equal to 0.4m2.
Patient has a clinical diagnosis of a fast-flow vascular malformation
Patient has received standard therapy for the vascular malformation or in which, in the opinion of the investigator, standard therapy is not appropriate

Note: standard therapy may include treatment with sirolimus. A minimum of 14 days since the last dose of sirolimus is required prior to starting treatment with mirdametinib

A documented genetic alteration in the RAS-MEK-ERK signalling pathway identified by genetic sequencing prior to enrolment in this study
Adequate performance status (Eastern Cooperative Oncology Group Performance Status Scale (ECOG) 0-2 in patients ≥ 16 years of age; Lansky > 50 in patients < 16 years of age)
Patient has a life expectancy ≥ 12 weeks
Participant has the ability to swallow capsules whole if the capsule dosage form is being utilized. This criterion does not apply if participant is utilizing the dispersible tablet form of study treatment
Adequate haematologic and end-organ function:

Haematology: Haemoglobin ≥ 9.0 g/dL; Absolute neutrophil count ≥ 1.5 x 109/L; Platelets ≥ 90 x 109/L, except where bleeding leading to low haemoglobin level is an indication for treatment, in which case haemoglobin < 9.0 g/dL is acceptable.
Hepatic function: alanine aminotransferase (ALT) and aspartate aminotransferase (AT) ≤ 2 x upper limit of normal (ULN); Total bilirubin < 1.5x ULN (isolated bilirubin > 1.5x ULN is acceptable if bilirubin is fractioned and direct bilirubin < 35%), except where impaired hepatic function is a consequence of the fast-flow malformation and hence is an indication for treatment, in which case impaired hepatic function is acceptable.
Renal function: Serum creatinine < 1.5 x ULN
Biochemistry: Calcium (corrected for serum albumin) and magnesium within normal limits or ≤ Grade 1 according to NCI-CTCAE v5.0 if judged clinically not significant by the investigator; Potassium within normal limits or corrected with supplements; Phosphate ≤ 1x ULN.

Patient agrees to abstinence or highly effective contraceptive measures if of childbearing potential (WOCBP)

Males who are sexually active must use a condom during intercourse while taking mirdametinib and for at least 90 days after stopping mirdametinib and should not father a child in this period. A condom is required to be used also by vasectomised men in order to prevent delivery of the drug via seminal fluid. In addition, male participants must not donate sperm during the study and for at least 90 days after stopping mirdametinib
Females who are of child-bearing potential, defined as all individuals physiologically capable of becoming pregnant, must use a highly effective method of contraception during study treatment and for at least 180 days after the last dose of any study treatment. Highly effective contraceptive methods include:
Total abstinence (when this is in line with the preferred and usual lifestyle of the subject) Periodic abstinence (eg., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception;
Female sterilisation (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or bilateral tubal ligation at least 6 weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the women has been confirmed by follow up hormone level assessment;
Male partner sterilisation (at least 6 months prior to screening) of the sole partner of a female participant on the study;
Use of oral (estrogen and progesterone), injected or implanted combined hormonal method of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormonal vaginal ring or transdermal hormone contraception. In the case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before taking study treatment.
Women are considered postmenopausal and not of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhoea with an appropriate clinical profile (i.e., age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least 6 weeks before taking study treatment. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered to be not of childbearing potential.

Patient has signed informed consent and is willing and able to comply with the protocol for the duration of the study, including undergoing treatment and scheduled visits and examinations

Exclusion Criteria:

History of hypersensitivity to any drugs or metabolites of MEK inhibitors or any of the excipients of mirdametinib
Severe infection requiring intravenous antibiotics within 4 weeks prior to enrolment
Patient has had a major surgical procedure within 4 weeks prior to enrolment
Prior use of a MEK inhibitor
Patient has abnormal QT interval corrected by Fridericia's formula (> 450 msec for male participants, > 470 msec for female participants, or > 480 msec for participants with bundle branch block) (triplicate ECG readings taken approximately 2 to 3 minutes apart and averaged) at Screening;
Patient is pregnant or lactating at the time of study registration. A pregnancy test is mandated for persons of child-bearing potential in the screening period
Impairment of GI function or GI disease that may significantly alter the absorption of the study drug based on investigator discretion
Any clinically significant active or known history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
Lymphoma, leukaemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years;
Breast cancer within the past 5 years;
Known history of Human Immunodeficiency Virus (HIV) infection (testing for HIV is not mandatory in screening)
Known history of severe cutaneous reactions like Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Erythema Multiforme (EM), or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
Patient has a history of, or evidence of, retinal pathology on ophthalmologic examination that is considered a risk factor for central serous retinopathy, retinal vein occlusion (RVO), or neovascular macular degeneration. Patients will be excluded from study participation if they have any of the following risk factors for RVO at

Screening:

Intraocular pressure > 21 mmHg;
Serum cholesterol > 7.8 mmol/L;
Serum triglycerides > 3.4 mmol/L;
Hyperglycaemia (fasting blood glucose > 7.0 mol/L );
Age specific hypertension
Patients ≥ 13 years of age with a blood pressure ≥ 140/90 mmHg
Patients ≤ 12 years of age with a blood pressure ≥ 95th percentile for age + 12 mmHg

Known history of glaucoma
Known history of clinically significant, uncontrolled heart disease and/or recent (within 6 months [24 weeks] of signing informed consent/assent) cardiac events including:

History of angina pectoris, coronary artery bypass graft (CABG), symptomatic pericarditis, or myocardial infarction within 6 months prior to the start of study treatment;
History of documented congestive heart failure (New York Heart Association functional classification III-IV);
History of clinically significant cardiac arrhythmias, (e.g., ventricular tachycardia), complete left bundle branch block, high grade Atrioventricular (AV) block (e.g. bifascicular block, Mobitz type II and third degree AV block without pacemaker in place);
Uncontrolled hypertension defined by a Systolic Blood Pressure (SBP) ≥ 140 mmHg and/or Diastolic Blood Pressure (DBP) ≥ 90 mmHg, with or without anti-hypertensive medication. Initiation or adjustment of antihypertensive medication(s) is allowed prior to screening;
Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or corrected QT interval > 470 msec at screening (using Fridericia correction);
Bradycardia (heart rate < 50 beats per minute at rest), by electrocardiogram (ECG) or pulse

Patient has recorded a left ventricular ejection fraction (LVEF) < 55% at Screening
Patient has experienced a cerebrovascular accident, transient ischaemic attach, or symptomatic pulmonary embolism within 6 months (24 weeks) of signing informed consent/assent.
Patient has other concurrent severe and/or uncontrolled medical conditions that would, in the Treating Physician's judgement, contraindicate administration of mirdametinib (eg. active or uncontrolled severe infection, chronic active hepatitis, immune-compromised, acute or chronic pancreatitis, uncontrolled high blood pressure)
Patient is unable to understand and comply with treatment instructions and requirements

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	The Royal Children's Hospital	Parkville	Victoria	Australia	3052

Sponsors and Collaborators

Murdoch Childrens Research Institute
Peter MacCallum Cancer Centre, Australia
Royal Children's Hospital

Investigators

Principal Investigator: Tony Penington, MBBS, FRACS., Study Principal Investigator
Principal Investigator: Stephen Luen, MBChB, FRACP., Principal Investigator
Principal Investigator: Lydia Pathmanathan, MBBS, FRACP., Principal Investigator